Two preclinical studies add mechanistic detail to how tumors survive therapy and how ferroptosis pathways can be modulated. One study links VRK2 to gemcitabine resistance in pancreatic cancer through a TPI1-mediated aerobic glycolysis pathway, while another reports that PARP1 drives neuropathic pain via GPX4-dependent ferroptosis in injured sensory neurons. These findings highlight different biological “levers” relevant to oncology and translational neuroscience: metabolic rewiring that supports chemotherapy tolerance, and ferroptosis regulation through GPX4 as a key molecular checkpoint. While neither readout is an immediate clinical pivot on its own, both point toward targetable nodes—metabolic drivers for resistance and GPX4-axis control for ferroptosis-related pathology—that could shape future drug discovery and combination strategies.